BUTALBITAL
Migraine Disorders
GlaxoSmithKlineSmall moleculePhase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 89/ 100
Competitive context
10 Active assets in the Migraine Disorders cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Naproxen IRCCS San Raffaele Roma | Phase 4 | A |
Xeomin® Merz Therapeutics GmbH | Phase 4 | BBB |
np101 NuPathe Inc. | Phase 3 | BBB |
Cobalamin The Cooper Health System | Phase 4 | BB |
Cyclic Microgestin 1/20 Endeavor Health | Phase 4 | BB |
View all 26 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →